A panel of human mAbs against JEV, including JEV-69, was generated from donors immunized with a GIII vaccine strain (JEV-SA14-14-2).
≥ 5.0 mg/ml
≤ 1.0 EU/mg as determined by the LAL method
≥95% monomer by analytical SEC
This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one year. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≥ -70°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
Standard Overnight on Blue Ice.
Other Applications Reported In Literature ?
N: JEV-69 effectively neutralizes the JEV-SA14-14-2 vaccine strain, GI strains 2372/79 and MAR 859, and GIV strain JKT 7887.
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Clone JEV-69 activity is directed against DIII-LR of the E protein. JEV-69 has no cross-reactivity to West Nile Virus or Zika Virus E proteins.
Japanese Encephalitis Virus (JEV) is a mosquito-borne, enveloped positive-stranded RNA virus in the Flavivirus genus endemic to Asia and parts of the western Pacific1. Symptomatic JEV infection is most common in children in areas of endemicity or travelers to those regions. Severe symptoms occur in ~1% of cases, with a case-fatality ratio of 20–30%. Survivors often have neurologic, cognitive, or psychiatric sequelae issues. Five JEV genotypes have been identified, and existing vaccines are derived from historically predominant GIII strains2.
References & Citations
1. Hills SL, Lindsey NP, Fischer M. Chapter 4: Travel-Related Infectious Diseases, Japanese Encephalitis. In: Brunette GW, Nemhauser JB, eds. 2020 CDC Yellow Book. CDC; National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Global Migration and Quarantine (DGMQ), Link Text
2. Fernandez E, Kose N, Edeling MA, et al. mBio. 9(1):e00008-18. 2018.
Products are for research use only. Not for use in diagnostic or therapeutic procedures.